Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 344-353

  Liang, Rongcai ^a,b,c   Li, Xiang ^a,c   Shi, Yanan ^a,c   Wang, Aiping ^b,c   Sun, Kaoxiang ^b,c   Liu, Wanhui ^b,c   Li, Youxin ^a,c  

^a JILIN UNIVERSITY   (China)

^b YANTAI UNIVERSITY   (China)

^c State Key Laboratory of Long acting and Targeting Drug Delivery System   (China)

Author keywords

Acylation; Exenatide; Microsphere; Poly(lactide co glycolide) (PLGA); Solution model

Indexed keywords

DIMETHYL SULFOXIDE; EXENDIN 4; MICROSPHERE; PLASTICIZER; POLYGLACTIN; WATER;

ACYLATION; ARTICLE; DRUG CONFORMATION; DRUG DEGRADATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; INFRARED SPECTROSCOPY; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; WATER ABSORPTION; WATER TRANSPORT;

EID: 84884136605     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.07.012     Document Type: Article

References (41)

1. Ahn, J.H., Park, E.J., Lee, H.S., Lee, K.C., Na, D.H., 2011. Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems. AAPS PharmSciTech 12, 1220-1226.
2. Andersen, N.H., Brodsky, Y., Neidigh, J.W., Prickett, K.S., 2002. Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorgan. Med. Chem. 10, 79-85. (Pubitemid 33095066)
3. Blasi, P., D'Souza, S.S., Selmin, F., DeLuca, P.P., 2005. Plasticizing effect of water on poly(lactide-co-glycolide). J. Control. Release 108, 1-9. (Pubitemid 41476669)
4. Brunner, A., Mäder, K., Göpferich, A., 1999. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm. Res. 16, 847-853. (Pubitemid 29284195)
5. Chae, S.Y., Choi, Y.G., Son, S., Jung, S.Y., Lee, D.S., Lee, K.C., 2010a. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J. Control. Release 144, 10-16.
6. Chae, S.Y., Jin, C.H., Shin, J.H., Son, S., Kim, T.H., Lee, S., Youn, Y.S., Byun, Y., Lee, M.S., Lee, K.C., 2010b. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J. Control. Release 142, 206-213.
7. Chi, E.Y., Krishnan, S., Randolph, T.W., Carpenter, J.F., 2003. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20, 1325-1336. (Pubitemid 37164039)
8. Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L.H., Langer, R., 1991. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8, 713-720.
9. Davidson, M.B., Bate, G., Kirkpatrick, P., 2005. Exenatide. Nat. Rev. Drug Discov. 4, 713-714.
10. Determan, A.S., Wilson, J.H., Kipper, M.J., Wannemuehler, M.J., Narasimhan, B., 2006. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations. Biomaterials 27, 3312-3320. (Pubitemid 43344342)
11. Dong, A., Prestrelski, S.J., Allison, D., Carpenter, J.F., 1995. Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J. Pharm. Sci. 84, 415-424.
12. Doyle, B.L., Pollo, M.J., Pekar, A.H., Roy, M.L., Thomas, B.A., Brader, M.L., 2005. Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation. J. Pharm. Sci. 94, 2749-2763. (Pubitemid 43265397)
13. Fu, K., Klibanov, A.M., Langer, R., 2000. Protein stability in controlled-release systems. Nat. Biotechnol. 18, 24-25. (Pubitemid 30041164)
14. Ghassemi, A.H., van Steenbergen, M.J., Barendregt, A., Talsma, H., Kok, R.J., van Nostrum, C.F., Crommelin, D.J.A., Hennink, W.E., 2012. Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres. Pharm. Res. 29, 110-120.
15. Houchin, M.L., Neuenswander, S.A., Topp, E.M., 2007. Effect of excipients on PLGA film degradation and the stability of an incorporated peptide. J. Control. Release 117, 413-420. (Pubitemid 46216583)
16. Hudson, F.M., Andersen, N.H., 2004. Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state. Pept. Sci. 76, 298-308. (Pubitemid 39468253)
17. Ibrahim, M.A., Ismail, A., Fetouh, M.I., Göpferich, A., 2005. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release 106, 241-252. (Pubitemid 41187434)
18. Jin, C.H., Chae, S.Y., Son, S., Kim, T.H., Um, K.A., Youn, Y.S., Lee, S., Lee, K.C., 2009. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J. Control. Release 133, 172-177.
19. Kidwai, S.A., Ansari, A.A., Salahuddin, A., 1976. Effect of succinylation (3-carboxypropionylation) on the conformation and immunological activity of ovalbumin. Biochem. J. 155, 171-180.
20. Kulasa, K.M., 2011. The current status of exenatide once weekly. Clin. Med. Insights Ther. 3, 221-232.
21. Kwak, H.H., Shim, W.S., Hwang, S., Son, M.K., Kim, Y.J., Kim, T.H., Yoon, Z.H., Youn, H.J., Lee, G.I., Kang, S.H., Shim, C.K., 2009. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in zucker diabetic fatty (ZDF) rats. Pharm. Res. 26, 2504-2512.
22. Lai, M.C., Topp, E.M., 1999. Solid-state chemical stability of proteins and peptides. J. Pharm. Sci. 88, 489-500. (Pubitemid 29220973)
23. Lucke, A., Kiermaier, J., Göpferich, A., 2002. Peptide acylation in poly(ahydroxy esters). Pharm. Res. 19, 175-181.
24. Lucke, A., Kiermaier, J., Göpferich, A., 2003. Acylation of peptides by lactic acid solutions. Eur. J. Pharm. Biopharm. 55, 27-33. (Pubitemid 36120492)
25. Murase, S., Yumoto, N., Petukhov, M.G., Yoshikawa, S., 1996. Acylation of the alpha-amino group in neuropeptide Y(12-36) increases binding affinity for the Y2 receptor. J. Biochem. Tokyo 119, 37-41.
26. Murty, S.B., Na, D.H., Thanoo, B.C., DeLuca, P.P., 2005a. Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int. J. Pharm. 297, 62-72. (Pubitemid 40720266)
27. Murty, S.B., Thanoo, B.C., Wei, Q., DeLuca, P.P., 2005b. Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation. Int. J. Pharm. 297, 50-61. (Pubitemid 40720265)
28. Murty, S.B., Wei, Q., Thanoo, B.C., DeLuca, P.P., 2004. In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil process. AAPS PharmSciTech 5, 1-10.
29. Na, D.H., DeLuca, P.P., 2005. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co- glycolide). Pharm. Res. 22, 736-742. (Pubitemid 40768585)
30. Na, D.H., Lee, J.E., Jang, S.W., Lee, K.C., 2007. Formation of acylated growth hormonereleasing peptide-6 by poly(lactide-co-glycolide) and its biological activity. AAPS PharmSciTech 8, E1-E5.
31. Park, E.J., Tak, T.H., Na, D.H., Lee, K.C., 2010. Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres. Arch. Pharm. Res. 33, 1111-1116.
32. Park, T.G., 1995. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 16, 1123-1130.
33. Shalaev, E.Y., Zografi, G., 1999. How does residual water affect the solid-state degradation of drugs in the amorphous state? J. Pharm. Sci. 88, 489-500.
34. Skovgaard, M., Kodra, J.T., Gram, D.X., Knudsen, S.M., Madsen, D., Liberles, D.A., 2006. Using evolutionary information and ancestral sequences to understand the sequence-function relationship in GLP-1 agonists. J. Mol. Biol. 363, 977-988. (Pubitemid 44573228)
35. Sophocleous, A.M., Zhang, Y., Schwendeman, S.P., 2009. A new class of inhibitors of peptide sorption and acylation in PLGA. J. Control. Release 137, 179-184.
36. Stevenson, C.L., Tan, M.M., 2000. Solution stability of salmon calcitonin at high concentration for delivery in an implantable system. J. Peptide Res. 55, 129-139. (Pubitemid 30079930)
37. Stevenson, C.L., 2009. Advances in peptide pharmaceuticals. Curr. Pharm. Biotechnol. 10, 122-137.
38. Van de Weert, M., Hennink, W.E., Jiskoot, W., 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17, 1159-1167.
39. Yang, T.H., Dong, A., Meyer, J., Johnson, O.L., Cleland, J.L., Carpenter, J.F., 1999. Use of infrared spectroscopy to assess secondary structure of human growth hormone within biodegradable microspheres. J. Pharm. Sci. 88, 161-165. (Pubitemid 29084725)
40. Zhang, Y., Schwendeman, S.P., 2012. Minimizing acylation of peptides in PLGA microspheres. J. Control. Release 162, 119-126.
41. Zhang, Y., Sophocleous, A.M., Schwendeman, S.P., 2009. Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts. Pharm. Res. 26, 1986-1994.